Sigyn Therapeutics (SIGY) Total Debt (2016 - 2025)

Sigyn Therapeutics has disclosed Total Debt across 10 years of filings, most recently posting $5.3 million for Q3 2025.

• In Q3 2025, Total Debt rose 197.27% year-over-year to $5.3 million; the TTM figure through Sep 2025 stood at $5.3 million (up 197.27% YoY), while the FY2024 annual figure was $4.0 million, up 109.21% from the prior year.
• Total Debt came in at $5.3 million for Q3 2025 at Sigyn Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $5.3 million in Q3 2025 to a low of $578254.0 in Q1 2021.
• Average Total Debt over 5 years is $2.0 million, with a median of $1.8 million recorded in 2024.
• Year-over-year, Total Debt sank 80.7% in 2021 and soared 250.55% in 2023.
• Over 5 years, Total Debt stood at $647202.0 in 2021, then surged by 152.88% to $1.6 million in 2022, then increased by 15.59% to $1.9 million in 2023, then jumped by 109.21% to $4.0 million in 2024, then soared by 34.51% to $5.3 million in 2025.
• Per Business Quant data, the three most recent Total Debt figures were $5.3 million in Q3 2025, $2.6 million in Q2 2025, and $2.4 million in Q1 2025.